Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

被引：0
作者：
Hideki Goto
Shinichi Makita
Koji Kato
Kota Tokushige
Taizo Fujita
Koichi Akashi
Koji Izutsu
Takanori Teshima
机构：
[1] Hokkaido University Faculty of Medicine,Department of Hematology, Graduate School of Medicine
[2] National Cancer Center Hospital,Department of Hematology
[3] Kyushu University Graduate School of Medical Sciences,Department of Medicine and Biosystemic Science
[4] Novartis Pharma K.K.,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Tisagenlecleucel; CAR T-cell therapy; Diffuse large B-cell lymphoma; JULIET;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1736 / 1743
页数：7
相关论文
共 50 条
[31]   Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective [J].
Wang, Xiao Jun ;
Wang, Yi-Ho ;
Li, Shing Chau Tony ;
Gkitzia, Christina ;
Lim, Soon Thye ;
Koh, Liang Piu ;
Lim, Francesca Lorraine Wei Inng ;
Hwang, William Ying Khee .
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :637-653
[32]   BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [J].
Westin, Jason ;
Bishop, Michael ;
Flinn, Ian ;
Borchmann, Peter ;
Jaeger, Ulrich ;
Gu, Jessie ;
Andreola, Giovanna ;
Pacaud, Lida ;
Schuster, Stephen .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S270-S271
[33]   Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone [J].
Cencini, Emanuele ;
Rocco, Melania ;
Ghio, Francesco ;
Simonetti, Federico ;
Cuccaro, Annarosa ;
De Marco, Federica ;
Consoli, Chiara ;
Bocchia, Monica ;
Fabbri, Alberto .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) :247-253
[34]   Predicting the risk of relapsed or refractory in patients with diffuse large B-cell lymphoma via deep learning [J].
Ma, Dongshen ;
Yuan, Yuqing ;
Miao, Xiaodan ;
Gu, Ying ;
Wang, Yubo ;
Luo, Dan ;
Fan, Meiting ;
Shi, Xiaoli ;
Xi, Shuxue ;
Ji, Binbin ;
Xiang, Chenxi ;
Liu, Hui .
FRONTIERS IN ONCOLOGY, 2025, 15
[35]   Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma [J].
Bo Xu .
European Journal of Clinical Pharmacology, 2022, 78 :707-719
[36]   Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma [J].
Malecek, Mary-Kate ;
Watkins, Marcus P. ;
Bartlett, Nancy L. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) :831-839
[37]   Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? [J].
Mondello, Patrizia ;
Steiner, Normann ;
Willenbacher, Wolfgang ;
Ferrero, Simone ;
Ghione, Paola ;
Marabese, Alessandra ;
Pitini, Vincenzo ;
Cuzzocrea, Salvatore ;
Mian, Michael .
ONCOLOGIST, 2016, 21 (09) :1107-1112
[38]   Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma [J].
Xu, Bo .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) :707-719
[39]   FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].
Kasamon, Yvette L. ;
Price, Lauren S. L. ;
Okusanya, Olanrewaju O. ;
Richardson, Nicholas C. ;
Li, Ruo-Jing ;
Ma, Lian ;
Wu, Yu-Te ;
Theoret, Marc ;
Pazdur, Richard ;
Gormley, Nicole J. .
ONCOLOGIST, 2021, 26 (10) :879-886
[40]   New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma [J].
Schipani, Mattia ;
Rivolta, Giulia Maria ;
Margiotta-Casaluci, Gloria ;
Mahmoud, Abdurraouf Mokhtar ;
Al Essa, Wael ;
Gaidano, Gianluca ;
Bruna, Riccardo .
CANCERS, 2024, 16 (01)
12345